Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Angela Nahl

Cornea and External Diseases Specialist La Jolla, CA Medical Doctor

NPI 1306173257 CMS profile 1025769

9834 Genesee Ave Ste 428, La Jolla, CA 92037

Open in the dashboard

General payments

$1,705

68 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Nahl of La Jolla, CA is reported in the CMS Open Payments database as having received $1,705 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $593 22
2024 General $343 11
2023 General $166 7
2022 General $57 3
2021 General $78 4
2020 General $135 10
2019 General $333 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Nahl
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Angela Nahl were reported at $593. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Angela Nahl Cornea and External Diseases Specialist median Middle half National median
2019 $333 $276 $111–$734 $163
2020 $135 $146 $48–$330 $114
2021 $78 $254 $116–$566 $132
2022 $57 $251 $106–$729 $149
2023 $166 $344 $149–$759 $160
2024 $343 $366 $170–$927 $164
2025 $593 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $396 15 payments
  2. Novartis Pharmaceuticals Corporation $358 21 payments
  3. Alcon Vision LLC $254 6 payments
  4. Carl Zeiss Meditec, Inc. $167 2 payments
  5. Oyster Point Pharma, Inc. $121 5 payments
  6. Tarsus Pharmaceuticals, Inc. $106 4 payments
  7. Harrow Eye, LLC $87 3 payments
  8. Shire North American Group Inc $48 3 payments
  9. Johnson & Johnson Surgical Vision, Inc. $25 1 payment
  10. AbbVie, Inc. $23 1 payment
  11. Other $119 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,650 65 payments
  2. Gift $19 1 payment
  3. Education $18 1 payment
  4. Entertainment $18 1 payment
Products named General payments · program years 2019–2025
  1. XIIDRA Ophthalmology $563 26 payments
  2. MIEBO $396 15 payments
  3. VisuMax $167 2 payments
  4. Rocklatan $119 1 payment
  5. Rhopressa $119 1 payment
  6. XIIDRA Ophthalmology $110 6 payments
  7. XDEMVY $106 4 payments
  8. VEVYE $87 3 payments
  9. TYRVAYA $57 2 payments
  10. ARGOS $57 2 payments
  11. Other $508 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record